A Study to Investigate ANS014004 in Participants With Locally Advanced or Metastatic Solid Tumors

ClinicalTrials.gov ID: NCT06307795

Public ClinicalTrials.gov record NCT06307795. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Aug 7, 2026, 5:58 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ANS014004 as a Single Agent in Participants With Locally Advanced or Metastatic Solid Tumors

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a Phase 1, first-in-human, open-label, multi-center study with the aim of exploring the safety, tolerability, PK, and preliminary anti-tumor activity of ANS014004 as a single agent in participants with locally advanced or metastatic solid tumors.

Study identification

NCT ID: NCT06307795
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1
Lead sponsor: Avistone Biotechnology Co., Ltd.; Industry
Enrollment: 63 participants

Conditions and interventions

Conditions

Locally Advanced or Metastatic Solid Tumors

Interventions

ANS014004 Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jun 23, 2024
Primary completion: Mar 31, 2027
Completion: Sep 30, 2027
Last update posted: Apr 16, 2026

2024 – 2027

United States locations

U.S. sites: 8
U.S. states: 8
U.S. cities: 8

Facility	City	State	ZIP	Site status
University of California, San Diego	San Diego	California	92093	Recruiting
Sarah Cannon Research Institute	Denver	Colorado	80218	Recruiting
Advent Health	Orlando	Florida	32804	Recruiting
Henry Ford Health Cancer	Detroit	Michigan	48202	Recruiting
NYU Langone Health	New York	New York	10003	Recruiting
The University of Texas - MD Anderson Cancer Center	Houston	Texas	77030	Recruiting
NEXT Oncology, Virginia	Fairfax	Virginia	22031	Recruiting
Swedish Cancer Institute	Seattle	Washington	98195	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 7 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06307795, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Apr 16, 2026 · Synced Aug 7, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06307795 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →